Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Other financing activities: 2020-2025

Historic Other financing activities for Maravai Lifesciences Holdings (MRVI) over the last 2 years, with Mar 2025 value amounting to $1.4 million.

  • Maravai Lifesciences Holdings' Other financing activities fell 42.18% to $1.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.3 million, marking a year-over-year increase of 2.86%. This contributed to the annual value of $9.3 million for FY2024, which is 50.57% up from last year.
  • As of Q1 2025, Maravai Lifesciences Holdings' Other financing activities stood at $1.4 million, which was down 38.20% from $2.2 million recorded in Q4 2024.
  • In the past 5 years, Maravai Lifesciences Holdings' Other financing activities registered a high of $2.4 million during Q1 2024, and its lowest value of $492,000 during Q1 2023.
  • In the last 3 years, Maravai Lifesciences Holdings' Other financing activities had a median value of $2.2 million in 2024 and averaged $1.9 million.
  • Its Other financing activities has fluctuated over the past 5 years, first soared by 383.33% in 2024, then slumped by 42.18% in 2025.
  • Maravai Lifesciences Holdings' Other financing activities (Quarterly) stood at $2.3 million in 2023, then dropped by 4.22% to $2.2 million in 2024, then crashed by 42.18% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q1 2025, $2.2 million for Q4 2024, and $2.3 million during Q3 2024.